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Abstract
Purpose of review—To highlight recent evidence supporting a concept that intestinal
inflammation is a mediator or contributor to development of obesity and insulin resistance.
Recent findings—Current views suggest that obesity-associated systemic and adipose tissue
inflammation promote insulin resistance, which underlies many obesity-linked health risks. Diet-
induced changes in gut microbiota also contribute to obesity. Recent findings support a concept
that high fat diet and bacteria interact to promote early inflammatory changes in the small intestine
that contribute to development of or susceptibility to obesity and insulin resistance. This review
summarizes the evidence supporting a role of intestinal inflammation in diet-induced obesity and
insulin resistance and discusses mechanisms.
Summary—The role of diet-induced intestinal inflammation as an early biomarker and mediator
of obesity, and insulin resistance warrants further study.
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Introduction
Obesity has reached pandemic proportions affecting millions of individuals in developing as
well as developed countries (1, 2). Obesity is associated with low-grade systemic
inflammation, which is considered a major mechanism driving insulin resistance in obese
individuals (3–5). Insulin resistance describes a condition in which elevated levels of plasma
insulin are required to maintain normal fasting or postprandial glucose levels (5). Insulin
resistance is considered a key initiating factor in the deleterious effects of obesity on health,
including glucose intolerance, dyslipidemia and increased risk of non-alcoholic fatty liver
disease (NAFLD), type 2 diabetes, atherosclerosis, hypertension, ischemic heart disease and
cancer (6, 7). Defining the sources, causes and mechanisms underlying the development of
inflammation and insulin resistance during progressive increases in body weight and
adiposity, is therefore central to the development of strategies and therapies to prevent or
limit the adverse effects of obesity on health. To date, a majority of studies have focused on
adipose tissue, particularly visceral adipose tissue, as the source of inflammation and
proinflammatory cytokines in obese humans or animal models as described in a recent
comprehensive review (7). This review will summarize recent evidence that diet-induced
inflammation in the intestine, particularly the small intestine, may represent an early event
that precedes and predisposes to obesity and insulin resistance. Evidence that intestinal
Correspondence: Pauline K. Lund, Ph.D. Department of Cell and Molecular Physiology University of North Carolina at Chapel Hill
111 Mason Farm Road, CB# 7545 Chapel Hill, North Carolina 27599-7574, USA Phone: (919) 966-1490 empk@med.unc.edu.
NIH Public Access
Author Manuscript
Curr Opin Clin Nutr Metab Care. Author manuscript; available in PMC 2013 May 10.
Published in final edited form as:













microbiota interact with diet to mediate intestinal inflammation and the mechanisms by
which these interactions may promote obesity or insulin resistance is also reviewed.
Obesity, adipocyte inflammation and insulin resistance
Current concepts (7) suggest that during obesity, hypertrophic or hypoxic adipocytes are
sources of proinflammatory cytokines including TNFα, IL-6 and monocyte chemoattractant
protein-1 (MCP-1). MCP-1 further exacerbates inflammation by recruiting monocytes from
the circulation and activating them to an M1 proinflammatory macrophage phenotype
characterized by secretion of TNFα, IL-1β, and IL-6. Proinflammatory cytokines
compromise insulin signaling by multiple mechanisms (Fig. 1). Cytokines induce
suppressors of cytokine signaling (SOCS) that bind the insulin receptor and limit its ability
to bind, and tyrosine phosphorylate insulin receptor substrates (IRS-1 or IRS-2), which are
critical to downstream signaling (8). Proinflammatory pathways activated by cytokines,
including NFκB, Jun-Kinase and IκB kinase (IKK), also induce serine phosphorylation of
IRS-1 and IRS-2 which limit the ability of IRS proteins to activate downstream pathways
(5). While adipocytes are unquestionably sources of inflammation in obesity, increasing
evidence suggests that obesogenic diets may stimulate inflammation in other organs (9, 10).
Intestinal inflammation in diet-induced obesity
Until recently, the potential role of intestinal inflammation as a mediator or contributor to
obesity has received relatively little attention. This is because chronic inflammatory bowel
diseases (IBD), such as Crohn's disease or ulcerative colitis, are associated with damage to
the intestinal epithelium, malabsorption and weight loss. However, it is important to
emphasize that the systemic and local tissue inflammation associated with diet-induced
obesity is less severe than in chronic IBD.
High fat diet and intestinal inflammation in animal models
The gastrointestinal tract is the first organ to be exposed to dietary components, such as diets
high in saturated fat, that promote obesity. In a recent study C57BL6 mice were exposed to
high-fat or low-fat diets (HFD and LFD), and expression of multiple proinflammatory
cytokines was assessed in small intestine and colon. Of many cytokines assayed, only TNFα
was up-regulated by HFD, and this occurred specifically in the ileum and within 2 to 6
weeks of HFD, preceding diet-induced weight gain and increased fat mass (9). Importantly,
the increases in ileal TNFα mRNA showed strong and significant correlations with the
degree of weight gain, increases in fat mass, and increases in plasma glucose or insulin (9).
In this study, there were no detectable increases in plasma TNFα or other cytokines,
suggesting that local up-regulation of ileal TNFα was a more sensitive measure of diet-
induced inflammation than circulating cytokine levels at least in this animal model (9). An
NFκBREEGFP reporter mouse expressing a transgene composed of NFκB response elements
(RE) driving enhanced green fluorescent protein (EGFP) was used as an independent model
to assess intestinal inflammation. Use of this model detected activation of NFκB-driven
transcription in ileum and to a lesser extent colon of mice fed HFD (9). Intriguingly, NFκB
activation was localized to multiple cell types, including intestinal epithelial cells, CD3+ or
CD45+ immune cells, endocrine cells and endothelial cells, but not resident F4/80 positive
intestinal macrophages (9). This study strongly suggests that intestinal inflammation and
proinflammatory signaling in multiple cell types is an early response to HFD and correlates
with subsequent development of obesity and insulin resistance. Two other recent studies
have demonstrated that high fat diet induces intestinal inflammation. de La Serre et. al. (11)
compared obesity-prone (DIO-P) or resistant (DIO-R) Sprague Dawley rats and found that
HFD up-regulated myeloperoxidase activity, a marker of inflammation, in ileum of only the
DIO-P animals. This is a significant observation linking intestinal inflammation specifically
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to HFD-induced obesity and not HFD alone. de Wit and colleagues performed gene
microarray on proximal, mid and distal small intestine of C57BL6 mice fed HFD and found
induction of macrophage migration inhibitory factor (MIF), which has been associated with
obesity and insulin resistance as well as enrichment of inflammation and interferon-γ-
induced gene subsets in ileum of mice fed HFD (12).
Evidence for and against intestinal inflammation in obese humans
Recent evidence demonstrates intestinal inflammation in obese humans. Spagnuolo et. al.
(13) examined a small cohort of severely obese children. Using fecal calprotectin and rectal
nitric acid as biomarkers of inflammation, they found that approximately 50% of obese and
glucose-tolerant children had elevated fecal calprotectin, while more than 80% of obese and
glucose-intolerant children had elevated rectal nitric oxide. This study indicates that
intestinal inflammation occurs in obese humans and suggests that relatively non-invasive
calprotectin or nitric oxide assays may be used to monitor obesity-associated intestinal
inflammation. The study was however limited to a small sample size and severely obese
children. Pendyala et. al. (14) examined proinflammatory cytokines and gene expression
profiles in colon mucosal biopsies from a small cohort of obese women before and after a
very low calorie diet to induce a loss of 10% body weight. They found that weight loss was
associated with significant reductions in mucosal TNFα, IL-1β, and IL-8 and dramatic
down-regulation of gene networks linked to proinflammatory signaling (15). Together, these
animal and human studies strongly support a concept that intestinal inflammation is linked
to obesity and insulin resistance.
Counterbalancing these studies are recent findings of Brignardello (16), who found no
evidence of colonic inflammation in obese compared to lean adults based on assays of fecal
caprotectin and leptin. However, the obese individuals in this study had signs of systemic
inflammation based on elevated plasma C-reactive protein but had fasting glucose levels
within the normal range. Thus, systemic inflammation and obesity in the absence of
detectable colonic inflammation was not associated with insulin resistance. Tiihonen et. al.
also found no increase in fecal calprotectin, TNFα, or IgA in obese vs. lean individuals
despite systemic inflammation and elevated plasma insulin (17). However, the lack of
inflammation detected in these latter human studies may indicate that the fecal biomarkers
do not have optimal sensitivity for detecting intestinal inflammation. Furthermore, in animal
models, HFD-induced inflammation is particularly evident in small intestine compared with
colon. Additional studies that specifically evaluate small bowel inflammation are therefore
required to definitively establish the impact of diet or obesity on intestinal inflammation in
humans.
Role of intestinal microbiota in obesity-associated intestinal inflammation
Compelling evidence supports a role of gut microbiota in diet-induced obesity (reviewed in
Musso 2011 (18). Although mechanisms are still to be defined, findings that germ-free (GF)
mice do not develop obesity or insulin resistance when placed on a HFD (19), provide
definitive evidence that gut microbiota must be present for deposition of excess dietary
energy intake into adipose tissue. Furthermore, colonization of germ-free mice with
microbiota from obese vs. lean animals resulted in increased total fat mass, demonstrating a
causal role of microbiota in diet-induced obesity (20). Recent findings demonstrate that
microbiota are also necessary for development of intestinal inflammation associated with
HFD and obesity. This evidence is based on our findings that GF mice fed HFD, as well as
being resistant to obesity, do not exhibit up-regulation of ileal or colonic TNFα(9). Thus
interactions between HFD and microbiota are required for HFD to induce intestinal
inflammation. de La Serre et. al. also found that HFD results in activation of ileal toll-like
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receptor 4 (TLR4) only in obesity-prone but not obesity-resistant rats (11). Since TLR4 is a
primary receptor mediating the proinflammatory effects of lipopolysaccharide (LPS) derived
from gram negative bacteria, this provides important evidence to link bacteria-induced
proinflammatory signaling in the intestine to the development of diet-induced obesity.
Intriguingly, HFD was associated with reduced levels of small intestinal alkaline
phosphatase (IAP), an enzyme that detoxifies LPS (11). Recent findings in IAP knockout
mice suggest that this enzyme is essential to preserve normal gut microbial homeostasis and
to protect against pathogenic bacteria (21). Thus HFD-induced decreases in IAP may be
important determinants of diet:microbe interactions that promote intestinal inflammation.
While much emphasis is currently placed on dysbiosis or altered microbial communities in
obesity, it is important to distinguish general diet-induced changes in microbial communities
from those specifically linked to obesity. For example, HFD altered gut microbial
populations in both obesity-prone and obesity-resistant rats (11). Similarly, another report
found that HFD led to comparable changes in microbiota in wild type mice that develop
obesity and in RELMβ knockout mice that are resistant to diet-induced obesity (22). These
findings demonstrate the need for caution in interpreting diet-induced changes in microbial
communities as causative factors in obesity. Dramatic increases in Enterobacteriales, a
member of the minor proteobacteria phylum, have been associated specifically with
development of intestinal inflammation and obesity in DIO-P rats fed HFD and were not
increased in DIO-R rats (11). This is interesting since enterobacteriaceae have recently been
linked to induction of spontaneous colitis in mouse models (23). Thus, the specific roles of
these particular bacteria in intestinal inflammation associated with obesity warrants further
study.
LPS as a key mediator of obesity or inflammation-associated insulin
resistance
A body of work by Cani and colleagues in mouse models demonstrates key roles of
increases in systemic LPS, a condition termed `metabolic endotoxemia' in the development
of obesity-associated insulin resistance (24–26). In a large study in healthy men, fat and
energy intake were also found to be strongly correlated with increased plasma LPS
concentrations (27). Another study in healthy humans showed that a high-fat/high-
carbohydrate meal induced a significant postprandial endotoxemia, coupled with increased
expression of TLR4, SOCS3, and NF-| B in circulating mononuclear immune cells (28). In
contrast, there were no increases in these proinflammatory mediators after meals rich in
fiber and fruits (28). Deopurkar et. al. compared the effects of isocaloric meals rich in
glucose, saturated fat, and orange juice on plasma LPS and inflammatory markers and found
that only saturated fat intake was linked to plasma LPS and systemic inflammation markers,
including NFκB, SOCS3, TNFα, IL-1β expression (29).
Current evidence suggests that diet-induced changes in intestinal permeability underlie the
elevated circulating LPS in obesity. HFD has been shown to reduce intestinal permeability
by affecting tight junction proteins, favoring increased translocation of LPS and potentially
other proinflammatory markers into the systemic circulation (11, 26). Antibiotics, prebiotics
or probiotic bacteria appear to ameliorate this effect and protect against weight gain,
systemic inflammation and insulin resistance (26, 30). A recent study suggests that LPS may
enter the lymph nodes and systemic circulation due to uptake into chylomicrons, which
mediate absorption of dietary fat from enterocytes (31). Thus, current views would support a
concept that inflammatory mediators absorbed from the gut due to diet:bacteria interactions
promote systemic inflammation and associated insulin resistance.
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Other mediators of intestinal inflammation due to diet:bacteria interactions
The complex and extensive interactions between host-dietary factors and microbiota (32) are
beyond the scope of this review, and readers are referred to an excellent recent review (18).
However it is important to recognize that many factors other than LPS may promote
intestinal inflammation in response to HFD. Diet can alter the profiles of short chain fatty
acids (SCFA) produced by bacterial fermentation of indigestible polysaccarides. Ratios of
the SCFA butyrate, propionate and acetate depend on diet pH and microbiota (18). Butyrate
has protective effects on intestinal epithelium by multiple mechanisms, including induction
of alkaline phosphates and protection against intestinal inflammation (33). Butyrate also
protects against HFD-induced obesity (34). Thus alterations in fecal SCFAs due to
diet:microbial interactions may favor intestinal inflammation. Other bacterial metabolites
such as secondary bile acids, lactate or phenolics, which have been associated with obesity
or insulin resistance (17), and linoleic acid or choline which have protective effects (18),
warrant further examination for roles in diet-associated intestinal inflammation.
TLR5 is protective against colitis and obesity
It is important to recognize that some bacteria-activated signaling pathways may be
protective against intestinal inflammation or obesity. TLR5 is a receptor that recognizes
bacterial flagellin, and when deleted in mouse models, a significant number of animals
developed colitis (35). However, after rederiving TLR5 null mice with standard microbiota,
the animals developed mild intestinal inflammation and by 20 weeks of age developed
obesity, preferential increases in visceral fat, dyslipidemia and insulin resistance (36). The
TLR5 null mice also had altered microbiota, which when transplanted to germ-free wild
type mice induced obesity. While this study does not definitively link intestinal
inflammation to obesity and insulin resistance, it emphasizes the key points that host
receptors for bacterial ligands can impact gut microbial communities and can be protective
against both intestinal inflammation and obesity.
Mechanisms by which gut inflammation itself may affect obesity or insulin
resistance
A key unanswered question is whether diet-induced intestinal inflammation itself, in
absence of systemic inflammation, is sufficient to initiate or promote insulin resistance or
obesity. Evidence in the literature points to several potential mechanisms. Vagal afferant
neurons (VAN) within the intestinal wall mediate satiety by a cholecystokinin/ CCK1R
pathway acting on the central nervous system feeding centers (37). HFD impairs sensitivity
of this pathway and promotes hyperphagia. Intestinal inflammation itself could act locally
on VAN to alter their sensitivity, although this remains to be formally tested. HFD and
bacteria and associated inflammation may also impact enteroendocrine cells which impact
feeding, metabolic pathways linked to obesity or insulin synthesis and secretion. Recent
studies demonstrate that a Western HFD increases serotonin availability by increasing
serotonin-synthesizing enterochromaffin cells, serotonin-synthesis genes and by decreasing
transporters for serotonin reuptake (38). While this has not yet been linked to diet-associated
intestinal inflammation, it is known that inflammation in other settings increases in
enterochromaffin cells. Serotonin reduces gut motility (38), and therefore HFD-induced
increases in serotonin and reduced motility may favor more efficient processing of ingested
nutrients or fat, or could mediate diet-induced alterations in specific microbiota. Glucagon-
like peptides (GLP) are synthesized in intestinal L cells and are derived from a common
intestinal proglucagon precursor. GLP-1 promotes insulin synthesis and secretion (39, 40).
GLP-2 promotes intestinal growth, has anti-inflammatory effects and improves gut
permeability (41–43). Both GLP-1 and GLP-2 are implicated as mediators of the beneficial
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effects of prebiotics to protect against weight gain, insulin resistance and diet-induced
increases in intestinal permeability (39, 40, 43, 44). Further studies are required to define
whether interactions between diet and endogenous bacteria, or their proinflammatory effects
on intestinal epithelium, affect L cells, GLP-1 or GLP-2 secretion or action.
Conclusions
Mounting evidence links HFD and diet-induced obesity to low-grade intestinal
inflammation. As indicated in the model in Fig. 2, we propose that diet interacts with
intestinal microbiota to promote early inflammatory changes in the intestine, particularly the
small intestine, which favor obesity and insulin resistance. Much remains to be done to
define precisely how mild intestinal inflammation favors obesity and insulin resistance, but
mechanisms likely include altered epithelial permeability, translocation of bacterial
products, up-regulation of proinflammatory cytokines, hormones produced from gut
endocrine cells and modulation of neural signaling between gut and brain that impacts
appetite or satiety. Future studies should dissect the temporal course and specific roles of
intestinal inflammation and associated functional effects in mediating obesity and insulin
resistance compared with those related to systemic and adipose inflammation.
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• Emerging evidence in animal models suggests that high fat diet and microbes
interact to promote low-grade inflammation in small intestine and to a lesser
extent colon
• Intestinal inflammation precedes and strongly correlates with diet-induced
obesity and insulin resistance
• Some but not all studies in humans link obesity and insulin resistance to
inflammation in the colon
• Better non-invasive biomarkers of diet:microbe-induced small intestinal
inflammation in humans are needed
• Intestinal inflammation may promote obesity and insulin resistance by multiple
mechanisms
• Future studies need to address the specific contributions of intestinal
inflammation vs. systemic or adipose inflammation to initiation and progression
of obesity and insulin resistance
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Figure 1. Mechanisms of insulin resistance linked to proinflammatory cytokines
Insulin activation of insulin receptor (IR) normally promotes tyrosine phosphorylation of
IRS-1 (or IRS-2) to mediate downstream signaling. Proinflammatory cytokines block
insulin/insulin receptor action by inducing suppressors of cytokine signaling (SOCS), which
prevent IRS-1 binding to IR and by promoting serine phosphorylation and inactivation of
IRS-1 via proinflammatory Jun-Kinase or NFκB pathways.
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Figure 2. Proposed roles of intestinal inflammation in obesity and insulin resistance
Top: current views of diet-associated obesity linking diet and gut microbes to development
of obesity, and subsequent systemic or adipose inflammation promoting insulin resistance.
Bottom: proposed, although not mutually exclusive, model of mechanism by which diet
interactions with gut microbes or metabolites induces early proinflammatory changes in the
intestine which, by the multiple mechanisms indicated, promote or increase susceptibility to
obesity and insulin resistance.
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